Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study
Open Access
- 7 March 2017
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 102 (6) , 1943-1950
Abstract
Context: Anaplastic thyroid cancer (ATC) is rare and a highly fatal malignancy. The role of programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) as prognostic and/or predictive markers in ATC is unknown. Objective: Multimodal therapy offers the best chance at tumor control. The objective of this study was to detect potential associations of PD-1/PD-L1 axis variables with outcome data in ATC. Design: Retrospective study of a uniformly treated cohort. Setting: Single institution retrospective cohort study. Patients or Other Participants: Sixteen patients who received intensity-modulated radiation therapy (15 had preceding surgery) were studied. Main Outcome Measure: Patients treated with multimodal therapy were followed and assessed for overall survival (OS) and progression-free survival (PFS). Results: All samples demonstrated PD-1 expression in inflammatory cells whereas tumor cells were primarily negative. PD-L1 was expressed on ATC tumor cells in most samples and showed mainly membranous staining. High PD-1 expression (>40% staining) in inflammatory cells was associated with worse overall survival (OS; hazard ratio, 3.36; 95% confidence interval, 1.00 to 12.96; P < 0.05) and trended toward worse PFS, whereas high PD-L1 expression in tumor cells (>33% staining) trended toward worse PFS and OS. Conclusion: PD-1/PD-L1 pathway proteins are highly expressed in ATC tumor samples and appear to represent predictive markers of PFS and OS in multimodality-treated ATC patients.Keywords
This publication has 31 references indexed in Scilit:
- Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencingHuman Molecular Genetics, 2015
- BRAF V600E in Papillary Thyroid Carcinoma Is Associated with Increased Programmed Death Ligand 1 Expression and Suppressive Immune Cell InfiltrationThyroid®, 2014
- Anaplastic Thyroid Carcinoma: A 25-year Single-Institution ExperienceAnnals of Surgical Oncology, 2014
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Prognostic Factors and Treatment Outcomes for Anaplastic Thyroid Carcinoma: ATC Research Consortium of Japan Cohort Study of 677 PatientsWorld Journal of Surgery, 2012
- Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: A critical re-evaluation including uniform pathologic reviewRadiotherapy and Oncology, 2011
- Multimodality therapeutic outcomes In anaplastic thyroid carcinoma: Improved survival in subgroups of patients with localized primary tumorsHead & Neck, 2011
- Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancerEndocrine-Related Cancer, 2008
- Anaplastic thyroid cancer in British Columbia 1985–1999: a population-based studyClinical Oncology, 2005
- Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004